Navigation Links
Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program
Date:11/8/2011

ividual safety measures of cardiac death, myocardial infarction (MI), and stent thrombosis remained low at two-year follow-up, demonstrating durable outcomes and successful transfer of the paclitaxel drug and polymer technology to the platinum chromium thin-strut platform.

Results were also presented from the PERSEUS Small Vessel trial, which compared the ION Stent in 223 patients with small vessels (greater than or equal to 2.25 to <2.75 mm diameter) to a matched historical control group of 125 patients treated with the Express® bare-metal stent.  The ION Stent demonstrated similar safety and superior performance at two years compared to the Express Stent with significantly lower propensity-adjusted rates of target lesion revascularization (TLR, 7.1 percent vs. 20.8 percent, p=0.009) in patients with lesions in small vessels.

PERSEUS-ATLAS Trial ComparisonIn an analysis of the PERSEUS and TAXUS ATLAS clinical trial programs, Dr. Kereiakes presented results that demonstrated safety outcomes favoring the ION (TAXUS Element) Stent compared to the Boston Scientific second-generation TAXUS® Liberte® Paclitaxel-Eluting Stent.  The study compared pooled patient-level data from 2,298 patients enrolled in the PERSEUS (ION Stent) and TAXUS ATLAS (TAXUS Liberte Stent) trials.  Propensity-matched results revealed that the ION Stent achieved significantly lower rates of MACE at two years (11.5 percent vs. 15.1 percent, p=0.04) and a numerically lower rate of TLF (8.2 percent vs. 11.0 percent, p=0.07), driven mainly by a reduction in MI (2.5 percent vs. 4.9 percent, p=0.02).  

"The significantly lower rates of MACE and MI in this propensity-matched analysis demonstrate that the platinum chromium alloy, new stent design and thinner struts of the ION Stent may favorably influence clinical outcomes," said Dr. Kereiakes.  "The PERSEUS trial results build confidence in this next-gener
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Boston College Researchers discover 2 early stages of carbon nanotube growth
2. Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories
3. Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation
4. Genethon and Childrens Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial
5. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
6. Boston Scientific to Webcast Conference Call Discussing First Quarter 2011 Financial Results
7. Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope
8. Boston Scientific Acquires Intelect Medical
9. Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinsons Disease
10. Boston College physics professor Willie Padilla receives PECASE award
11. Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... (Nasdaq: IMRX ) today announced that the ... most current lot release request for,urokinase drug product. ... with extended,expiration dating. Urokinase, ImaRx,s first commercially available,FDA-approved ... the treatment of acute massive pulmonary embolism., ...
... Jan. 24 Hologic, Inc.,(Nasdaq: HOLX ), ... imaging products and interventional devices dedicated to,serving the ... release its,first quarter fiscal 2008 operating results on ... conjunction with the release, management will,host a conference ...
... the Waldorf-Astoria Hotel in New York ... ... Group (GLG) and the,Biotechnology Industry Organization (BIO) today announced a collaborative,agreement designed ... BIO CEO & Investor Conference., "We,re thrilled to have this unique ...
Cached Biology Technology:ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating 2ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating 3Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference 3
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... Haemophilia is a hereditary blood disease, primarily affecting ... potentially life-threatening 'bleeds'. About one in 6000 Australian ... or mild form. People with haemophilia rely on ... , Professor Denisa Wagner and her Harvard colleagues ...
... may be due to excessive programmed cell death of immune ... cell death in virus-infected T cells in vitro, but have ... concentrations. The mechanisms for these paradoxical data are unclear, as ... in HIV patients in vivo. , In a study appearing ...
... that interfere with the cells that are trying to ... fatty acids surrounding the tumors may give a boost ... in the September issue of the Journal of Lipid ... journal. , Several forms of anti-cancer therapy rely on ...
Cached Biology News:Promising therapies for haemophilia & heart disease 2Researchers discover new tumor defense system 2
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... incubation trays are disposable trays ... antigens that have been blotted ... has eight 10.5 cm x ... strips cut from blotted membrane ...
... the state-of-the-art in permanent mounting media. ... preservation of immunohistochemical organic insoluble substrates ... New Fuchsin, and any other organic ... sections. Clarin can be used for ...
... sophisticated DNA analysis and protein analysis tasks, but ... sequence analysis product. Imagine having the ability to ... performed each time you have a new sequence, ... exactly how your output will look for each ...
Biology Products: